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ABSTRACT
Objective: To investigates how the use of HIV-1 resistance tests inﬂ uences physician decision-making. 
Methods: Ten experienced reference physicians from the Brazilian Network for Drug Resistance each 
received ten patients’ case histories. The selected patients had experienced at least two virological failures. 
First, reference physicians were asked to empirically select a new regimen for each patient. Second, after 
genotype report (ViroSeq 2.6) was provided, and physicians were again asked to select a new regimen 
considering this additional information. Finally, they were asked to select a regimen after receiving a vir-
tual phenotype result (vircoTYPE 3.9.00). Results: In 79% of the cases, physicians changed their empirical 
choice of regimen after receiving the genotype report, resulting in an increase in the mean number of ac-
tive drugs from 1.8 to 2.2 (p = 0.0003), while the average number of drugs/regimen remained at 4.0. After 
receipt of the virtual phenotype report, additional changes were made in 75% of the patient cases, result-
ing in an increase in the number of active drugs to 2.8 (p < 0.0001), while the average number of drugs/
regimen remained at 4.0. After receipt of the genotype report, 48% of the changes were in NRTIs, 29% 
were in NNRTIs and 60% were in PIs; after consideration of the virtual phenotype, 61%, 10% and 49% 
of the changes, respectively, were in these categories of drugs. Fourteen percent of the physicians rated 
the genotype report as “extremely useful”, whereas 34% rated the subsequent virtual phenotype report as 
“extremely useful” (p = 0.0003). Conclusions: Resistance testing has a signifi cant impact on physicians’ 
choices of antiretroviral salvage therapies, and it promotes the selection of more active drugs.
Keywords: genotype, virtual phenotype, antiretroviral resistance, Brazil.
[Braz J Infect Dis 2010;14(5):489-494]©Elsevier Editora Ltda.
INTRODUCTION
Although antiretroviral therapy provides signifi -
cant reductions in HIV-related mortality and mor-
bidity, these reductions may be limited in duration.1 
In some developing countries where antiretrovirals 
are widely available, one study showed that the me-
dian time to loss of treatment benefi t was approxi-
mately 14 months among treatment-naïve pa-
tients.2 As a result of antiretroviral failure, resistance 
has been increasingly detected,3 even in developing 
countries. An analysis of 791 samples submitted for 
resistance testing in Brazil revealed that 96.6% of 
the samples had primary resistance-associated mu-
tations present in the reverse transcriptase coding 
region, and 90.3% had mutations in the protease 
coding region. Multi-drug resistance was com-
mon, with 36.8% of samples revealing resistance to 
at least one drug from each therapeutic class.4 Fur-
thermore, antiretroviral resistance has been associ-
ated with disease progression and death.5,6
Prospective randomized clinical trials have 
shown that, among patients on salvage therapy, 
the selection of antiretrovirals with the aid of re-
sistance testing results in improved virological 
response.7-11 Furthermore, studies have shown 
that the combination of expert advice and geno-
type testing further improves virologic outcomes 
among patients on salvage therapy.10 However, an 
understanding of how resistance testing inﬂ uences 
decision-making by individual physicians has not 
been established.
The Brazilian Network for Antiretroviral Re-
sistance is comprised of more than 100 trained ex-
pert physicians (designated ‘reference physicians’) 
who analyze the results of genotypic tests per-
formed in the Brazilian public system and make 
recommendations to treating physicians. These 
reference physicians are trained to act as clinical vi-
rologists for HIV antiretroviral salvage therapy. In 
the Brazilian Network for Antiretroviral Resist-
ance, genotype tests ordered by attending phy-
sicians are analyzed by reference physicians, 
and salvage regimen recommendations made 
by the reference physicians are delivered to the at-
tending physicians with the test results to optimize 
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the effi cacy of salvage regimens. In this study, we evaluated the 
impact of two different genotypic analysis systems, ViroSeq 2.6 
and Virtual Phenotype (VircoTYPE HIV-1, 3.9.00), on the choice 
of antiretroviral salvage therapy suggested by reference physicians 
of the Brazilian Network for Antiretroviral Resistance.
METHODS
Ten genotyping reference physicians from the Brazilian 
Network for Antiretroviral Resistance were selected to 
participate in the study. The reference physicians were se-
lected on the basis of level of experience, the most experi-
enced physicians being chosen. The selected doctors had 
been acting as reference physicians for at least 5 years and 
treating HIV/AIDS for at least 10 years. Training in salvage 
therapy and interpretation of resistance tests for the ref-
erence physicians occurs annually in a four-day workshop 
organized exclusively for this purpose. Five out of the ten 
chosen physicians play a key role in the preparation of the 
training workshops for the network of reference physicians. 
The reference physicians were selected from different Bra-
zilian states based on the prevalence of AIDS cases in each 
state: three doctors from São Paulo (SP), three from Rio de 
Janeiro (RJ), one from Ribeirão Preto (SP), one from Belo 
Horizonte (MG), one from Salvador (BA) and one from 
Porto Alegre (RS). One hundred consecutive patients pre-
senting with virologic failure were selected based on the 
availability of both a genotype (ViroSeq 2.6, Celera Diag-
nostics, Alameda, California, USA) and virtual phenotype 
(VircoTYPE HIV-1, 3.9.00), reports. All patients were on 
antiretrovirals at the time plasma samples were collected 
for genotyping. Patients evaluated in this study were selected 
from the metropolitan area of São Paulo (SP), and all the 
laboratory work was performed at the Retrovirology Labo-
ratory of the Universidade Federal de São Paulo, Brazil.
The study goals were (a) to observe the decision-making 
process and (b) to evaluate the antiretroviral regimen selected 
and recommended by these reference physicians for 100 salvage 
patients (second or subsequent failure) treated in the Brazilian 
public system (10 cases/doctor) for whom genotyping was being 
performed for the fi rst time. The study was conducted in the fol-
lowing steps. It should be pointed out that at the time this study 
was conducted, nonpeptidic PIs, integrase inhibitors, and CCR5 
antagonists were not a choice for salvage therapy, since this drugs 
were not available in Brazil.
Step 1: Recording patient history
Reference physicians recorded patient histories, including both 
clinical and treatment histories, in an electronic record format.
Step 2: Baseline evaluation, treatment recommendation 
and reference physicians self-reported observations
Reference physicians evaluated the patients’ medical history re-
ports, including antiretroviral exposures, histories of intol-
erance, side effects, allergic reactions, viral loads and T cell 
counts. After this evaluation, the reference physicians were 
asked to empirically choose a preferred treatment option 
for the patients. Reference physicians were asked to sum-
marize the bases on which they provided their recom-
mended treatment options; these responses were recorded 
in the form of a self-completed electronic questionnaire.
Step 3: Genotype resistance test evaluation, treatment 
recommendation and reference physicians self-reported 
observations
Following the completion of Step 2, reference physicians 
received genotyping reports (ViroSeq 2.6). Upon receipt of 
these reports, the reference physicians again made treat-
ment recommendations based on these fi rst resistance test 
results and provided their recommended treatment options 
in the form of a self-completed electronic anamnesis.
Step 4: Virtual phenotype sequential resistance test 
evaluation, treatment recommendation and reference 
physicians self-reported observations
Following the completion of Step 3, reference physicians 
received virtual phenotype reports (VircoTYPE HIV-1 
3.9.00) and again made treatment recommendations based 
on these resistance test results; the physicians also recorded 
the reasons for their fi nal recommendations. The rationale 
for offering the virtual phenotype results after the geno-
typing results was the hypothesis that the more quantifi ed 
assessments of resistance (i.e., the calculated fold change 
vis-à-vis the clinical cutoffs) provided by the virtual phe-
notypes would provide added value in this particular pop-
ulation of patients in which extensive resistance is expected 
to have occurred.
Finally, the reference physicians provided (via electronic 
self-completed anamnesis.) summaries of the added value 
offered by each report they had received during the study. 
This summary used a 4-point qualitative assessment scale to 
evaluate the utility of each resistance interpretation system 
in helping to select a new drug regimen.
Statistical analyses
To compare the number of active drugs selected for each 
regimen choice, the activities of the selected drugs were 
scored using a continuous phenotypic sensitivity score 
(cPSS) calculated as the sum of the activities of each drug 
in the regimen. Each drug was given a score of 1 if the 
phenotypic fold-change (FC) was less than the virtual 
phenotype lower clinical cutoff (CCO1), 0 if the FC was 
greater than the higher clinical cutoff (CCO2), or a value 
between 0 and 1 if the FC was between clinical cutoffs; 
where clinical cutoffs were not available for a particular 
drug, a cPSS score of 1 was used for FCs less than the bio-
logic cutoff (BCO) and 0 for FCs greater than the BCO.
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RESULTS
Demographics and treatment history
The patients selected for this study were 53% male, and 
the median age was 37 years. The selected patients had un-
dergone a median of three antiretroviral regimens over an 
average period of 5.2 years. The average number of drugs 
used during this period was 5.7. The average CD4 count 
was 356 cells/mm3 (ranging from 4 to 2,072), and the aver-
age viral load was 198,157 copies/mL (5.3 log
10
).
Resistance profiles of patients’ viruses
The resistance profi le of each patient’s virus was determined 
from the latest genotype available for the patient (the same 
genotype used in Step 2 of the study). Patients had a median 
Table 1. Percentage of change in the regimen, number of active drugs according to the phenotypic susceptibil-
ity score (PSS), and average number of drugs suggested by reference physicians, in each phase of the study
 Changed  Number of Total # drugs
 regimen active drugs in regimen p value 
 selection
Phase I – no  
1.8 4  resistance test
Phase II – genotype 
79% 2.2 4 p = 0.0004report
Phase III – virtual 
75% 2.8 4 p > 0.0001phenotype report
Figure 1: Prevalence of mutations in the group of analyzed 
patients. Panel A depicts the Nucleoside Analog Reverse 
Transcriptase Inhibitors (NRTI) mutations, Panel B the Non-
nucleoside Analog Reverse Transcriptase inhibitors (NNRTI) 
mutations, and panel C the protease inhibitors (PI) mutations. 
TAM: thymidine analog mutations.
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number of four NRTI mutations, with 52% having any thymi-
dine analog mutation (TAM), 78% having 184I/V, and 12% 
having 74V (Figure 1). A median of one NNRTI mutation 
was identifi ed among the patients, with 42% having 103N 
and 24% having 190G/S (Figure 1). Patients had a median 
number of two primary PI mutations, with 47% having 
46I/L, 42% having a substitution at codon 82, and 40% hav-
ing 90M (Figure 1).
Changes in regimen selection following resistance 
interpretation
In 79% of the 100 cases, the reference physicians changed 
their empirical choice of regimen after receiving the gen-
otype (Table 1). Following subsequent receipt and con-
sideration of a virtual phenotype report, reference phy-
sicians made additional regimen changes in 75% of the 
492
patient cases. Categorization of regimen changes by ARV drug 
class showed that following receipt of the genotype, the highest 
proportion of switches were made to or from protease inhibi-
tors (60%) followed by changes to or from NRTIs (48%), with 
the least number of switches being made to or from NNRTIs 
(29%). Following subsequent receipt of the virtual phenotype, 
additional NRTI changes were made in 61% of regimens, addi-
tional PI changes in 49% of regimens, and NNRTIs were again 
changed the least (10%). Therefore, the genotype report had a 
higher impact on the choice of PI and the virtual phenotype 
report had a higher impact on the choice of NRTI. Changes 
to a class were counted under any of the following conditions: 
replacement of 1 or more drugs by 1 or more different drugs of 
the same class, deletion of any drug from the class, or addition 
of 1 or more drugs from a previously non-selected class.
Changes in individual drug selection
The drugs most frequently used for salvage therapy were 
TDF (20%), 3TC (17%), LPV/r (16%), EFV (9%) and AZT 
(6%). The drugs most frequently changed based on geno-
type were LPV/r and TDF, which together accounted for 
16.7% of genotype changes, and the ratio of deletions to ad-
ditions for both was approximately 2:1 (Table 2). The next 
Table 2. Drugs most frequently changed
  Following genotype                            Following virtual phenotype
All drug changes 
including deletions  
n = 216 n = 216 n = 216 n = 235 n = 235 n = 235from and additions 
to a regimen 
NRTIs
 All Changes Changes All Changes Changes
  changes from to changes from to
 AZT 11.6% 9.3% 2.3% 12.8% 8.5% 4.3%
 3TC 14.4% 11.6% 2.8% 13.2% 11.5% 1.7%
 ddI 6.9% 4.6% 2.3% 18.3% 9.4% 8.9%
 d4T 5.1% 3.7% 1.4% 26.8% 13.6% 13.2%
 ABC 8.8% 5.6% 3.2% 7.7% 4.7% 3.0%
 FTC 0.5% 0.5% 0.0% 0.4% 0.4% 0.0%
 TDF 16.7% 11.6% 5.1% 14.0% 11.1% 3.0%
NNRTIs      
 EFV 9.7% 5.6% 4.2% 3.4% 1.3% 2.1%
 NVP 1.4% 0.9% 0.5% 0.0% 0.0% 0.0%
 DLV 2.3% 0.0% 2.3% 1.3% 0.9% 0.4%
PIs      
 IDV 0.9% 0.9% 0.0% 0.4% 0.0% 0.4%
 IDV/r 0.0% 0.0% 0.0% 0.4% 0.0% 0.4%
 NFV 1.9% 1.4% 0.5% 0.0% 0.0% 0.0%
 SQV 6.5% 2.3% 4.2% 6.4% 4.7% 1.7%
 SQV/r 0.0% 0.0% 0.0% 2.6% 0.4% 2.1%
 APV 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
 APV/r 2.3% 0.0% 2.3% 4.3% 1.7% 2.6%
 fAPV 0.5% 0.5% 0.0% 0.0% 0.0% 0.0%
 fAPV/r 1.9% 1.4% 0.5% 0.9% 0.4% 0.4%
 LPV/r 16.7% 10.2% 6.5% 10.6% 5.5% 5.1%
 ATV 0.5% 0.0% 0.5% 0.0% 0.0% 0.0%
 ATV/r 2.3% 1.4% 0.9% 2.6% 0.9% 1.7%
 TPV/r 6.5% 0.0% 6.5% 8.1% 4.7% 3.4%
  100% 100% 100% 100% 100% 100%
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most frequently changed drugs based on the genotype 
report were 3TC (14.4%) and AZT (11.6%), and again 
deletions from the regimen outnumbered additions. Fol-
lowing the virtual phenotype report, d4T (26.8%) and 
ddI (18.3%) were the drugs most frequently changed, and 
in both cases, deletions from the regimen marginally out-
numbered additions. These drugs were followed by 3TC 
(13.2%) and AZT (12.8%). Darunavir was not an option 
for the reference physicians, since it was not registered 
at the time the study was conducted. Enfuvirtide was a 
choice in 17% of the empirically based regimens, in 38% 
of the genotype-based regimens, and in 34% of the virtual 
phenotype-based regimens. In seven cases where Enfuvir-
tide was chosen on the basis of the genotype report, the 
physician decided to choose an antiretroviral other than 
Enfuvirtide after receiving the virtual phenotype report.
Results of changes in regimen selection
The regimen changes that occurred after receipt of the 
genotype report resulted in an increase in the mean 
number of active drugs from 1.8 to 2.2 (p = 0.0003), 
while the total number of drugs selected remained at a 
mean of 4.0. Subsequent changes following considera-
tion of the virtual phenotype report resulted in a further 
increase in the number of active drugs from 2.2 to 2.8 
(p < 0.0001), while the mean number of drugs per regi-
men remained at 4.0.
Treatment cost after regimen selection
Some of the available drugs in Brazil are generic and rep-
resent a lower cost for the government. Non-generic drugs 
include Abacavir, Tenofovir, Lopinavir, Atazanavir, Am-
prenavir, Nelfinavir, and Enfuvirtide. The average costs 
of empirically based, genotype-based and virtual pheno-
type-based salvage therapies were US$20.16, US$31.99 
and US$28.81/day, respectively (ANOVA: empirical vs. 
genotype, p < 0.001; empirical vs. virtual phenotype, 
p < 0.001; genotype vs. virtual phenotype, non-signifi-
cant). The individual costs of the drugs in Brazil can be 
seen at www.aids.gov.br.
Physician assessment of the utility of the resist-
ance interpretations
Following consideration of the genotypic interpretations 
and subsequently of the virtual phenotypes, the refer-
ence physicians assessed the utility of each in helping 
to select treatment options (Table 3). The majority of 
the expert physicians found the genotypic information 
to be useful (88%, extremely/very/moderately useful). 
The majority (84%) also found the subsequent virtual 
phenotype to be useful. Fourteen percent of the refer-
ence physicians rated the genotype as “extremely useful”, 
whereas 34% rated the subsequent virtual phenotype as 
“extremely useful” (p = 0.0003).
DISCUSSION
In this study we analyzed the impact of resistance test in-
terpretations on medical opinion in HIV-1 salvage therapy. 
For this purpose, we used ten very experienced Brazilian 
reference physicians, all well-trained to provide HIV salvage 
therapy guidance and genotypic resistance interpretation to 
attending physicians within the Brazilian public system. We 
found that resistance test interpretations played a key role in 
inﬂ uencing the opinions of this group of physicians: 79% of 
the time they chose a different antiretroviral after analyzing 
the genotypic profi le of the patient’s virus and 75% of the 
time the group further changed their drug selection when a 
virtual phenotype interpretation was offered after the geno-
type report. We believe that the phenotype-based report 
may further inﬂ uence the physician’s decision (especially in 
cases where extensive resistance is documented in the geno-
type result) due to the quantitative nature of the phenotype 
result and the presence of clinical cutoffs. It is possible that 
the quantitative aspect of the phenotypic interpretation 
(given by the fold change values) enables physicians to build 
a more active antiretroviral backbone, as drugs with values 
closer to the lower cutoff tend to be chosen. Indeed, geno-
typic resistance testing, phenotypic resistance testing and 
virtual phenotypes9,12,13 have been proven to be effective for 
optimizing salvage therapy regimens and to provide a bet-
ter virologic response than standard care. It is interesting 
to note that virtual phenotypes have been found to provide 
similar or even better salvage regimens when compared to 
conventional phenotype tests.12,13
It has been shown that the PSS correlates well with viro-
logic response to salvage therapy, with the number of active 
drugs being proportional to the decline in viral load.14 For 
this reason, we used the PSS to calculate the average number 
of active drugs prescribed in each study phase. Interestingly, 
the use of a resistance test increased the number of active 
drugs, and use of the virtual phenotype resulted in a still 
higher average number of active drugs (2.8). It is of note that 
the average number of drugs available for use in a regimen 
was the same for each study phase, and thus, the increase in 
Table 3. Utility of the resistance tests according to 
the reference physicians
 Genotype Virtual  
   phenotype
Extremely useful 13% 34%
Very useful 51% 25%
Moderately useful 23% 25%
Did not make any difference 13% 16%
Total 100% 100%
Diaz, Sucupira, Vergara et al.
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the number of active drugs was not due to an increase in the 
number of available antiretrovirals, but rather to a tendency 
to select drugs with more activity. In spite of the higher cost 
of the antiretrovirals prescribed after resistance tests in this 
study, the increase in potential virologic effi cacy with the use 
of more active and durable regimens may conceivably make 
salvage therapy guided by resistance testing cost-effective, as 
has been previously described.15
One caveat of this study is that the reference physicians 
analyzed patients followed by other attending physicians in-
stead of patients followed by them. Therefore, although the 
reference physicians used all of the available clinical data and 
data about antiretroviral tolerance, side effects and allergies 
for each case, it is possible that in the real world, some of 
the suggested drugs or combinations of drugs would not be 
used. Thus, we acknowledge that although there is a signifi -
cant impact of resistance test interpretation on physicians’ 
decision-making, this effect may not translate into a large 
change in the choice of drugs. Therefore, the increase in the 
number of active drugs prescribed may be overestimated in 
this study compared to what would happen in real life.
Nonetheless, it has been shown that resistance tests not 
only positively impact virologic outcome but also impact 
patients’ survival,16 and these impacts clearly result from the 
inﬂ uence of resistance test interpretations on the choice of 
antiretrovirals prescribed by physicians providing care to 
HIV-infected patients.
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